In patients with recurrent or metastatic HNSCC, treatment with monoclonal antibodies targeting epidermal growth factor receptor (EGFR), such as cetuximab, has shown promising outcomes when used in combination with radiation therapy.5 The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.